Rita Humeniuk
Maze (United States)(US)Gilead Sciences (United States)(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, COVID-19 Clinical Research Studies, Chronic Myeloid Leukemia Treatments, Lymphoma Diagnosis and Treatment, SARS-CoV-2 and COVID-19 Research
Most-Cited Works
- → Carcinoma-Associated Fibroblast–Like Differentiation of Human Mesenchymal Stem Cells(2008)899 cited
- → A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance(2007)417 cited
- → Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects(2020)262 cited
- → Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor(2021)132 cited
- → MiR-24 Tumor Suppressor Activity Is Regulated Independent of p53 and through a Target Site Polymorphism(2009)103 cited
- → The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy(2021)76 cited
- → Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1(2020)72 cited
- → Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia(2020)59 cited
- → Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies(2021)54 cited
- → Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance(2009)51 cited